micronavigation ELN path item Leukemias path item AML path item Publications  · 
Workpackage 5

Publications



  1. Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, Sanz M, Guerci A, Miguel JS, de la Serna J, Garo C, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux F.: Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience.
    Leukemia 19:230-233, 2005
    Subjects: AML
  2. Albrecht O, Serve H, Tchinda J, Zühlsdorf M, Büchner T, et al.: Acute myeloid leukemia presenting with uterus tumor.
    Ann Hematol 85: 58-59, 2005
    Subjects: AML
  3. Amadori S, Fenaux P, Ludwig H, O’Dwyer M, Sanz M: Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Curr Med Res Opin 21:403-411, 2005
    Subjects: AML
  4. Berdel W E, Kumilova E, Kolkmeyer A, et al.: Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.
    Ann Hematol 84: 771-773, 2005
    Subjects: AML
  5. de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, Guerci A, San Miguel J, de la Serna J, Stoppa AM, Reman O, Stamatoulas A, Fey M, Cahn JY, Sotto JJ, Bourhis JH, Parry A, Chomienne C, Degos L, Fenaux P.: Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All-Trans-Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group.
    J Clin Oncol 23:120-126, 2005
    Subjects: AML
  6. Büchner T et al.: Akute und chronische myeloische Leukämie
    Harrisons Innere Medizin 16. Auflage ABW Wissenschaftsverlag 2005, Kap. 96
    Subjects: AML
  7. Büchner T: Akute myeloische Leukämien (AML)
    Schmoll et al. Kompendium Intern Onkol 4. Auflage 2006 Springer Verlag, Kap. 41.1
    Subjects: AML
  8. Büchner T, Berdel W E, Schoch C, et al.: Treatment of AML in biological subgroups
    Hematology 10: 281-85, 2005
    Subjects: AML
  9. Büchner T, Berdel W E, Wörmann B et al.: Treatment of older patients with AML
    Crit Rev Oncol Hematol 56: 247-259, 2005
    Subjects: AML
  10. Büchner T, Berdel WE, Schoch C et al.: Therapeutic outcome in prognostic subgroups of de-novo acute myeloid leukemia (AML) and the role of the age factor. A study in 1834 patients of 16-84 years
    J Clin Oncol 23 Suppl 1: 573s, 2005
    Subjects: AML
  11. Büchner T, Döhner H, Ehninger G, Ganser A, Hehlmann R, Hoelzer D, Niederwieser D, Pfirrman M, Hasford J: Experiences from a network of AML trials using general up-front randomization and a common standard arm
    ELN Information Letter No.1, 6/2005
    Subjects: AML
  12. Büchner T: Treatment of acute myeloid leukemia: Recent results and new directions.
    Acta Haematologica Polanica 36 Suppl 2: 3-9, 2005
    Subjects: AML
  13. Büchner T: Treatment of acute myeloid leukemia (AML): Recent results and new directions.
    IJHOBMT 2: 1-5, 2005
    Subjects: AML
  14. Büchner T, Berdel WE, Serve HL et al.: Risk adapted therapy for acute myeloid leukemia (AML).
    Haematologica 90 Extraordinario 1: 323-25, 2005
    Subjects: AML
  15. Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, Thomas X, Guerci A, Fegueux N, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Ferrand A, Sanz M, Chomienne C, Fenaux P, Dombret H.: Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group
    Leukemia 19:1153-1160, 2005
    Subjects: AML
  16. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Al-Ali H, Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Bruno B, Maziarz RT, Petersen F, Storb R.: Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
    J Clin Oncol 2006 Jan 20;24(3):444-53
    Subjects: SCT
  17. Hiddemann W, Spiekermann K, Buske C, Feuring-Buske M, Braess J, Haferlach T, Schoch C, Kern W, Schnittger S, Berdel W E, Wörmann B, Heinecke A, Sauerland M C, Büchner T.: Towards a pathogenesis-oriented therapy of acute myeloid leukemia.
    Crit Rev Oncol Hematol 56: 261-274, 2005
    Subjects: AML
  18. Lengfelder E, Saußele S, Weisser A, Büchner T et al.: Treatment concepts of acute promyelocytic leukaemia
    Crit Rev Oncol Hematol 56: 261-74, 2005
    Subjects: AML
  19. Messerer D, Engel J, Hasford J et al.: Allogeneic transplantation from an HLA-matched family donor in first complete remission of acute myeloid leukemia had an adverse impact on quality of life in patients followed for at least five years after treatment: a survey of the German AML Intergroup on 525 patient.
    Blood 106 Suppl 1: 221a, 2005
    Subjects: AML · SCT
  20. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
    Cancer Res 65:2662-7 (2005)
    Subjects: AML
  21. Sanz MA, Fenaux P, Lo-Coco F.: Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence
    Haematologica 90:1231-1235, 2005
    Subjects: AML
  22. Sanz MA, Lo-Coco F.: Standard practice and controversial issues in front-line Therapy of acute promyelocytic leukemia.
    Haematologica 90:840-845, 2005
    Subjects: AML
  23. Sanz MA, Tallman MS, Lo-Coco F.: Practice points, consensus, and controversial issues in the management of patients with newly diagnosed acute promyelocytic leukemia.
    Oncologist 10:806-14, 2005
    Subjects: AML
  24. Sanz MA, Tallman MS, Lo-Coco F.: Tricks of the trade for the appropriate management of acute promyelocytic leukemia.
    Blood 105:3019-3025, 2005
    Subjects: AML
  25. Sanz MA, Vellenga E, de la Serna J, Martín G.: High antileukemic efficacy, excellent tolerance and high degree of compliance using all-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia.
    Am J Oncol Rev 4:333-343, 2005
    Subjects: AML
  26. Saußele S, Berger U, Aul C, Büchner T et al.: Klinische Forschung im Kompetenznetz „Akute und chronische Leukämien“
    Medizinische Klinik (in press)
    Subjects: General Topic
  27. Schaich M; Schlenk RF; Al-Ali HK; Dohner H; Ganser A; Heil G; Illmer T; Krahl R; Krauter J; Sauerland C; Buchner T; Ehninger G: Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup
    Haematologica 2007 Jun;92(6):763-70 [pmid:0017550848]
    Subjects: AML
  28. Schaich M,Schlenk RF,Al-Ali HK,Döhner H,Ganser A,Heil G,Illmer T,Krahl R,Krauter J,Sauerland C,Büchner T,Ehninger G: Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.
    Haematologica 2007 Jun;92(6):763-70 [pmid:17550848]
    Subjects: AML
  29. Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Büchner T et al.: Conditioning with 8-GY total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
    Blood 106: 3314-21, 2005
    Subjects: AML

 

Print this Document   Sitemap   Contact  
EUTOS
EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe More ...


 
top